Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies

BACKGROUND: Programmed cell death-1 (PD-1) inhibitor-related hematologic toxicities are a category of rare but clinically serious and potentially life-threatening adverse events; however, little is known about their risks across different treatment regimens and tumor types. The objective of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Jiang-Dong, Wang, Ying, Wan, Yue, Wu, Yong-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996859/
https://www.ncbi.nlm.nih.gov/pubmed/29922039
http://dx.doi.org/10.2147/DDDT.S167077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996859/
https://www.ncbi.nlm.nih.gov/pubmed/29922039
http://dx.doi.org/10.2147/DDDT.S167077

Ejemplares similares